Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Fragile X disappointments upset autism ambitions

The clinical failure of two large mGluR5-antagonist programmes in Fragile X syndrome has forced drug developers to rethink trial design and target selection for neurodevelopmental indications.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mullard, A. Fragile X disappointments upset autism ambitions. Nat Rev Drug Discov 14, 151–153 (2015). https://doi.org/10.1038/nrd4555

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4555

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing